Genetic Technologies Limited (GENE)
USD 0.77
(0.0%)
USD 0.77
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 6.18 Million AUD | -58.36% |
| 2023 | 14.85 Million AUD | -28.58% |
| 2022 | 20.8 Million AUD | -9.45% |
| 2021 | 22.97 Million AUD | 46.94% |
| 2020 | 15.63 Million AUD | 378.8% |
| 2019 | 3.26 Million AUD | -47.05% |
| 2018 | 6.16 Million AUD | -49.08% |
| 2017 | 12.1 Million AUD | -8.89% |
| 2016 | 13.28 Million AUD | -35.86% |
| 2015 | 20.71 Million AUD | 207.91% |
| 2014 | 6.72 Million AUD | -19.12% |
| 2013 | 8.31 Million AUD | -49.4% |
| 2012 | 16.44 Million AUD | 84.28% |
| 2011 | 8.92 Million AUD | 7.76% |
| 2010 | 8.27 Million AUD | -62.83% |
| 2009 | 22.27 Million AUD | -7.75% |
| 2008 | 24.14 Million AUD | 15.25% |
| 2007 | 20.95 Million AUD | -6.64% |
| 2006 | 22.44 Million AUD | -23.31% |
| 2005 | 29.26 Million AUD | 30.71% |
| 2004 | 22.38 Million AUD | -25.97% |
| 2003 | 30.24 Million AUD | -8.35% |
| 2002 | 33 Million AUD | -16.84% |
| 2001 | 39.68 Million AUD | 348.58% |
| 2000 | 8.84 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 8.46 Million AUD | 0.0% |
| 2024 Q1 | 8.46 Million AUD | -43.01% |
| 2024 FY | 6.18 Million AUD | -58.36% |
| 2024 Q4 | 6.18 Million AUD | 0.0% |
| 2024 Q3 | 6.18 Million AUD | -26.93% |
| 2023 Q3 | 14.85 Million USD | -5.34% |
| 2023 Q4 | 14.85 Million AUD | 0.0% |
| 2023 FY | 14.85 Million AUD | -28.58% |
| 2023 Q1 | 15.69 Million USD | -24.55% |
| 2023 Q2 | 15.69 Million AUD | 0.0% |
| 2022 FY | 20.8 Million AUD | -9.45% |
| 2022 Q2 | 22.54 Million AUD | 0.0% |
| 2022 Q3 | 20.8 Million AUD | -7.72% |
| 2022 Q4 | 20.8 Million AUD | 0.0% |
| 2022 Q1 | 22.54 Million AUD | -1.87% |
| 2021 Q3 | 22.97 Million AUD | 21.91% |
| 2021 Q1 | 18.84 Million AUD | 20.54% |
| 2021 Q2 | 18.84 Million AUD | 0.0% |
| 2021 FY | 22.97 Million AUD | 46.94% |
| 2021 Q4 | 22.97 Million AUD | 0.0% |
| 2020 FY | 15.63 Million AUD | 378.8% |
| 2020 Q1 | 4.34 Million AUD | 33.04% |
| 2020 Q2 | 4.34 Million AUD | 0.0% |
| 2020 Q3 | 15.63 Million AUD | 259.91% |
| 2020 Q4 | 15.63 Million AUD | 0.0% |
| 2019 Q2 | 4.11 Million AUD | 0.0% |
| 2019 Q3 | 3.26 Million AUD | -20.67% |
| 2019 Q1 | 4.11 Million AUD | -33.25% |
| 2019 Q4 | 3.26 Million AUD | 0.0% |
| 2019 FY | 3.26 Million AUD | -47.05% |
| 2018 Q2 | 8.54 Million AUD | 0.0% |
| 2018 FY | 6.16 Million AUD | -49.08% |
| 2018 Q4 | 6.16 Million AUD | 0.0% |
| 2018 Q3 | 6.16 Million AUD | -27.85% |
| 2018 Q1 | 8.54 Million AUD | -29.42% |
| 2017 Q2 | 16.47 Million AUD | 0.0% |
| 2017 FY | 12.1 Million AUD | -8.89% |
| 2017 Q4 | 12.1 Million AUD | 0.0% |
| 2017 Q3 | 12.1 Million AUD | -26.51% |
| 2017 Q1 | 16.47 Million AUD | 23.97% |
| 2016 Q3 | 13.28 Million AUD | -22.78% |
| 2016 FY | 13.28 Million AUD | -35.86% |
| 2016 Q1 | 17.21 Million AUD | -16.93% |
| 2016 Q4 | 13.28 Million AUD | 0.0% |
| 2016 Q2 | 17.21 Million AUD | 0.0% |
| 2015 Q3 | 20.71 Million AUD | 500.31% |
| 2015 FY | 20.71 Million AUD | 207.91% |
| 2015 Q2 | 3.45 Million AUD | 0.0% |
| 2015 Q4 | 20.71 Million AUD | 0.0% |
| 2015 Q1 | 3.45 Million AUD | -48.71% |
| 2014 Q3 | 6.72 Million AUD | -55.72% |
| 2014 FY | 6.72 Million AUD | -19.12% |
| 2014 Q2 | 15.19 Million AUD | 0.0% |
| 2014 Q1 | 15.19 Million AUD | 82.68% |
| 2014 Q4 | 6.72 Million AUD | 0.0% |
| 2013 Q3 | 8.31 Million AUD | -35.31% |
| 2013 Q1 | 12.86 Million AUD | -21.78% |
| 2013 Q4 | 8.31 Million AUD | 0.0% |
| 2013 FY | 8.31 Million AUD | -49.4% |
| 2013 Q2 | 12.86 Million AUD | 0.0% |
| 2012 Q2 | 16.14 Million AUD | 0.0% |
| 2012 FY | 16.44 Million AUD | 84.28% |
| 2012 Q4 | 16.44 Million AUD | 0.0% |
| 2011 Q4 | 8.92 Million AUD | 0.0% |
| 2011 FY | 8.92 Million AUD | 7.76% |
| 2011 Q2 | 12.46 Million AUD | 0.0% |
| 2010 Q4 | 8.27 Million AUD | 0.0% |
| 2010 FY | 8.27 Million AUD | -62.83% |
| 2010 Q2 | 12.71 Million AUD | 0.0% |
| 2009 Q4 | 17.97 Million AUD | 0.0% |
| 2009 FY | 22.27 Million AUD | -7.75% |
| 2009 Q2 | 22.17 Million AUD | 0.0% |
| 2008 FY | 24.14 Million AUD | 15.25% |
| 2008 Q4 | 24.14 Million AUD | 0.0% |
| 2008 Q2 | 28.51 Million AUD | 0.0% |
| 2007 Q4 | 20.95 Million AUD | 0.0% |
| 2007 FY | 20.95 Million AUD | -6.64% |
| 2007 Q2 | 29 Million AUD | 0.0% |
| 2006 Q4 | 22.44 Million AUD | 0.0% |
| 2006 Q2 | 38.7 Million AUD | 0.0% |
| 2006 FY | 22.44 Million AUD | -23.31% |
| 2005 Q4 | 29.26 Million AUD | 0.0% |
| 2005 FY | 29.26 Million AUD | 30.71% |
| 2005 Q2 | 21.81 Million AUD | 0.0% |
| 2004 FY | 22.38 Million AUD | -25.97% |
| 2003 FY | 30.24 Million AUD | -8.35% |
| 2002 FY | 33 Million AUD | -16.84% |
| 2001 FY | 39.68 Million AUD | 348.58% |
| 2000 FY | 8.84 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 96.866% |
| Applied DNA Sciences, Inc. | 13.65 Million USD | 54.683% |
| Aspira Women's Health Inc. | 6.26 Million USD | 1.205% |
| Biodesix, Inc. | 99.09 Million USD | 93.757% |
| BioNexus Gene Lab Corp. | 11.39 Million USD | 45.731% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | 24.752% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | 24.752% |
| Bionano Genomics, Inc. | 214.4 Million USD | 97.115% |
| CareDx, Inc | 484.61 Million USD | 98.723% |
| Check-Cap Ltd. | 25.01 Million USD | 75.271% |
| Castle Biosciences, Inc. | 477.81 Million USD | 98.705% |
| DarioHealth Corp. | 96.38 Million USD | 93.582% |
| Exact Sciences Corporation | 6.47 Billion USD | 99.904% |
| Fulgent Genetics, Inc. | 1.27 Billion USD | 99.514% |
| Guardant Health, Inc. | 1.78 Billion USD | 99.654% |
| ICON Public Limited Company | 16.98 Billion USD | 99.964% |
| IDEXX Laboratories, Inc. | 3.25 Billion USD | 99.81% |
| Illumina, Inc. | 10.11 Billion USD | 99.939% |
| Intelligent Bio Solutions Inc. | 13.77 Million USD | 55.101% |
| iSpecimen Inc. | 15.81 Million USD | 60.892% |
| Standard BioTools Inc. | 323.06 Million USD | 98.085% |
| MDxHealth SA | 129.13 Million USD | 95.209% |
| 23andMe Holding Co. | 395.16 Million USD | 98.434% |
| Medpace Holdings, Inc. | 1.65 Billion USD | 99.627% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 99.484% |
| Mainz Biomed B.V. | 15.4 Million USD | 59.851% |
| ENDRA Life Sciences Inc. | 6.75 Million USD | 8.404% |
| NeoGenomics, Inc. | 1.68 Billion USD | 99.632% |
| Neogen Corporation | 4.58 Billion USD | 99.865% |
| Inotiv, Inc. | 856.53 Million USD | 99.278% |
| Natera, Inc. | 1.45 Billion USD | 99.575% |
| OPKO Health, Inc. | 2.01 Billion USD | 99.692% |
| Psychemedics Corporation | 13.27 Million USD | 53.38% |
| Prenetics Global Limited | 254.17 Million USD | 97.566% |
| Prenetics Global Limited | 254.17 Million USD | 97.566% |
| Precipio, Inc. | 18.1 Million USD | 65.822% |
| Personalis, Inc. | 225.09 Million USD | 97.252% |
| RadNet, Inc. | 2.88 Billion USD | 99.786% |
| Sera Prognostics, Inc. | 95.44 Million USD | 93.518% |
| Sotera Health Company | 3.13 Billion USD | 99.802% |
| Neuronetics, Inc. | 115.83 Million USD | 94.659% |
| Star Equity Holdings, Inc. | 86.97 Million USD | 92.887% |
| Star Equity Holdings, Inc. | 86.97 Million USD | 92.887% |
| Trinity Biotech plc | 59.43 Million USD | 89.591% |
| Twist Bioscience Corporation | 776.4 Million USD | 99.203% |
| Exagen Inc. | 56.94 Million USD | 89.136% |